Lead-212 PSV359 Therapy for Patients With Solid Tumors
A phase 1/2 trial of [203Pb]Pb-PSV359 in pancreatic ductal adenocarcinoma, gastric & gastro-oesophageal junction cancer, oesophageal cancer, colorectal cancer, ovarian cancer and head and neck squamous cell carcinoma, run by Perspective Therapeutics, now recruiting.
Overview
Lead-212 PSV359 Therapy for Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT06710756 by Perspective Therapeutics, with 112 participants planned, started 2025-04-28 and due to reach its primary completion in 2028-01-31. Interventions recorded: [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359.
Similar pages
not linked directly; found by shared links- TrialTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Shares Perspective Therapeutics, Lead-212 and the tag pipeline.
- TrialStudy of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Shares Lead-212 and the tag pipeline.
- TrialMC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Shares Perspective Therapeutics, Lead-212.
- AgentLead-212 VMT-alpha-NET
Shares Lead-212 PSV359, Perspective Therapeutics, Lead-212.
- IdeaFund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211
Shares Perspective Therapeutics, Lead-212.
- IndicationNon-small cell lung cancer
Shares Lead-212 PSV359, Perspective Therapeutics.